The invention concerns Low Molecular Weight Heparin having an average molecular weight by weight comprised between 3,000 and 6,500 D and containing nitro groups - ONO2 covalently bonded to the saccharide structure, and pharmaceutical compositions comprising it. The Low Molecular Weight Heparin according to the invention is disclosed for use as a medicament, more specifically for use in the treatment and prevention of pathologies associated with dysfunction of haemostatic and cardiovascular systems.
